This event, which is designed for sellside research analysts and institutional investors, will take place at The Westin New York at Times Square, 270 West 43rd Street, New York, New York 10036.
GAITHERSBURG, Md., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced that the company will host an analyst and investor day on December 7, 2017 in New York City.
This event, which is designed for sellside research analysts and institutional investors, will take place at The Westin New York at Times Square, 270 West 43rd Street, New York, New York 10036 from 8:00 AM EST to 12:30 PM EST. The entire event will be webcast. Institutional and analyst attendees who choose to participate onsite must register, as space is limited. To RSVP or for more information, please contact Jordan Kohnstam of Westwicke Partners at jordan.kohnstam@westwicke.com or 443-450-4189.
Event Agenda
Presentations will be made by various members of Emergent senior management, including: President and CEO, Daniel J. Abdun-Nabi; EVP and CFO, Robert G. Kramer, Sr.; EVP, Corporate Development and General Counsel, Atul Saran; EVP, Business Operations, Adam R. Havey; SVP and CSO, W. James Jackson, Ph.D.; and the heads of each of the business units as well as key focus areas, including Sales & Marketing and External Development & Government Contracting.
In addition, former Congressman Mike Rogers, who served as Chairman of the U.S. House Permanent Select Committee on Intelligence, will discuss the U.S. government’s perspective on public health threats.
Webcast Information
A live webcast, including slide presentations and a video, will be available on the Investor Relations section of the company’s website at http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-irhome. The audio, accompanying presentations, and video will be archived on the company’s website after completion of the event.
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com
Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
KiefferL@ebsi.com
